PD-1 inhibition and (Non-)Hodgkin lymphoma: promising outcomes in an emerging field
PD-1 inhibition and (Non-)Hodgkin lymphoma: prom
PD-1 inhibition and (Non-)Hodgkin lymphoma: prom
Finding the way among a multitude of targets and
Advancing treatment in patients with mantle cell
Approaching marginal zone lymphoma from various
Insights from early clinical trials on targeted
Management of CLL patients: BTK inhibition and b
What is new in Waldenström’s macroglobulinemia?
多种实体瘤中的新型组合方法 乐伐替尼(lenvatinib)加派姆单抗 抗血管生成多激酶
卵巢癌:将PARP抑制更进一步 尼拉帕利(niraparib)的个性化用量 根据NOVA
将创新从实验室带入临床实践 Andrés Cervantes, MD, PhD, 西班牙